logo
Share SHARE
FONT-SIZE Plus   Neg

IGI Laboratories Names Jason Grenfell-Gardner CEO

IGI Laboratories, Inc. (IG) Monday said Jason Grenfell-Gardner has been appointed President and Chief Executive Officer of the firm, effective July 30.

Jason Grenfell-Gardner brings significant experience in the pharmaceutical industry, with a special focus on generics. He was most recently the Senior Vice President of Sales and Marketing for West-Ward Pharmaceuticals, the US Subsidiary of Hikma Pharmaceuticals.

Jason had a key role in the senior management team there, which grew the business from just over $100 million in 2008 to over $300 million in 2011. He strengthened West-Ward's presence in the sterile injectable space through the acquisition of Baxter International, Inc.'s multisource injectable business in 2011.

Jason originally joined Hikma Pharmaceuticals to lead its initial public offering in 2004, and later headed its business development efforts.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Best Inc., a 23.4 percent owned by e-commerce major Alibaba Group, filed for Initial Public Offering in the U.S. According to the filing, Best expects to offer $750 million american depository shares. We urge Investors to take advantage of the weakness in the shares of Applied Optoelectronics, Inc. (AAOI), as we believe the stock has at least 15% upside from current levels. The stock is down along with many of the stocks in the Fiber optical component universe with an exposure to China. Nestle SA's shares were gaining around 4 percent in Zurich trading after billionaire activist investor Daniel Loeb's hedge fund Third Point LLC bought a $3.5 billion stake in the Swiss food giant. The acquisition of about 1.25% stake in Nestle would put pressure on the company to find ways to accelerate growth.
comments powered by Disqus
Follow RTT